Table 2. Univariate and multivariate survival analysis of AML patients from SEER database.
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Sex (Male vs. Female) | 1.068 (1.043-1.094) | <0.001 | 1.085 (1.058-1.111) | <0.001 |
| Age (> 55 vs. 16-55 years) | 2.428 (2.359-2.500) | <0.001 | 2.352 (2.283-2.423) | <0.001 |
| Race (Non-White vs. White) | 0.912 (0.883-0.942) | <0.001 | 0.987 (0.955-1.020) | 0.426 |
| AML subtype (Others vs. AML, NOS) | 0.674 (0.658-0.691) | <0.001 | 0.727 (0.709-0.745) | <0.001 |
| Adjuvant therapy (Radiation vs. None ) | 0.578 (0.543-0.616) | <0.001 | 0.751 (0.704-0.800) | <0.001 |
| Marital Status (Married vs. Unmarried ) | 0.875 (0.855-0.897) | <0.001 | 0.802 (0.782-0.822) | <0.001 |
| Age (years) 16-35 36-55 56-75 76-95 >95 |
Reference 1.426 (1.348-1.507) 1.592 (1.552-1.634) 1.648 (1.618-1.679) 1.634 (1.557-1.715) |
<0.001 <0.001 <0.001 <0.001 |
Reference 1.426 (1.342-1.508) 2.331 (2.205-2.464) 3.899 (3.677-4.134) 5.603 (4.665-6.730) |
<0.001 <0.001 <0.001 <0.001 |
| Race Black White Other (American Indian/AK Native, Asian/Pacific Islander) Unknown |
0.924 (0.884-0.966) Reference 0.952 (0.932-0.974) 0.855 (0.770-0.950) |
<0.001 <0.001 0.003 |
1.008 (0.963-1.054) Reference 1.024 (0.980-1.070) 0.831 (0.607-1.138) |
0.740 0.297 0.249 |
| AML subtype AML, NOS Acute promyelocytic leukemia Acute myelomonocytic leukemia AML with RPN1/EVI1 fusion gene AML with CBFB/MYH11 fusion gene AML with RUNX1/RUNX1T1 fusion gene AML with MLLT3/MLL fusion gene AML with RBM15/MKL1 fusion gene AML with DEK/NUP214 fusion gene AML with minimal differentiation AML without maturation AML with maturation AML with myelodysplasia-related changes Acute erythroid leukemia Acute megakaryoblastic leukemia Therapy-related myeloid neoplasm |
Reference 0.295 (0.277-0.314) 0.984 (0.965-1.003) 0.887 (0.713-1.102) 0.773 (0.744-0.804) 0.867 (0.846-0.889) 0.942 (0.915-0.970) 0.910 (0.819-1.012) 0.982 (0.946-1.020) 1.006 (0.997-1.015) 0.978 (0.971-0.984) 0.977 (0.972-0.983) 0.978 (0.973-0.983) 0.993 (0.986-1.001) 1.009 (0.998-1.020) 0.810 (0.789-0.830) |
<0.001 0.094 0.279 <0.001 <0.001 <0.001 0.082 0.349 0.188 <0.001 <0.001 <0.001 0.087 0.095 <0.001 |
Reference 0.375 (0.352-0.399) 1.056 (1.015-1.097) 0.795 (0.413-1.527) 0.465 (0.398-0.542) 0.607 (0.536-0.687) 0.820 (0.690-0.975) 0.581 (0.277-1.220) 0.863 (0.490-1.519) 1.070 (0.995-1.152) 0.913 (0.859-0.970) 0.854 (0.807-0.903) 0.716 (0.679-0.756) 0.901 (0.822-0.987) 1.216 (1.055-1.402) 0.055 (0.038-0.078) |
<0.001 0.006 0.490 <0.001 <0.001 0.025 0.151 0.609 0.070 0.003 <0.001 <0.001 0.026 0.007 <0.001 |
| Adjuvant therapy None Beam radiation or radioisotopes Unknown |
Reference 0.524 (0.490-0.562) 1.136 (1.050-1.229) |
<0.001 0.002 |
Reference 0.703 (0.655-0.754) 1.114 (0.952-1.304) |
<0.001 0.179 |
| Marital Status Married Widowed Never married Divorced Separated |
Reference 1.813 (1.757-1.871) 0.786 (0.758-0.814) 1.072 (1.025-1.122) 0.942 (0.827-1.073) |
<0.001 <0.001 0.002 0.268 |
Reference 1.312 (1.267-1.357) 1.167 (1.125-1.211) 1.148 (1.098-1.201) 1.145 (1.006-1.304) |
<0.001 <0.001 <0.001 0.041 |
Abbreviation: CSS, cancer-specific death; HR, hazard ratio; CI, confidence interval; AML, acute myeloid leukemia; NOS, no other specific; SEER, Surveillance, Epidemiology and End Results